|
π
|
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
20 auth.
L. Sequist,
J. Yang,
N. Yamamoto,
K. O'Byrne,
V. Hirsh,
T. Mok,
Sarayut Lucien Geater,
S. Orlov,
C. Tsai,
M. Boyer,
...
W. Su,
J. Bennouna,
T. Kato,
V. Gorbunova,
K. Lee,
R. Shah,
D. Massey,
V. Zazulina,
M. Shahidi,
M. Schuler
|
11 |
2013 |
11
π
|
|
π
|
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
15 auth.
Yi-long Wu,
Caicun Zhou,
Cheng-ping Hu,
Jifeng Feng,
Shun Lu,
Yunchao Huang,
Wei Li,
M. Hou,
Jianhua Shi,
K. Lee,
...
Chongrui Xu,
D. Massey,
Miyoung Kim,
Yang Shi,
Sarayut Lucien Geater
|
10 |
2014 |
10
π
|
|
π
|
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
28 auth.
J. Yang,
Yi-long Wu,
M. Schuler,
M. Sebastian,
S. Popat,
N. Yamamoto,
Caicun Zhou,
Cheng-ping Hu,
K. O'Byrne,
Jifeng Feng,
Shun Lu,
Yunchao Huang,
Sarayut Lucien Geater,
K. Lee,
C. Tsai,
...
V. Gorbunova,
V. Hirsh,
J. Bennouna,
S. Orlov,
T. Mok,
M. Boyer,
W. Su,
K. Lee,
T. Kato,
D. Massey,
M. Shahidi,
V. Zazulina,
L. Sequist
|
10 |
2015 |
10
π
|
|
π
|
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
23 auth.
Keunchil Park,
E. Tan,
K. O'Byrne,
Li Zhang,
M. Boyer,
T. Mok,
V. Hirsh,
J. Yang,
K. Lee,
Shun Lu,
...
Yuankai Shi,
Sang-We Kim,
J. Laskin,
Dong-Wan Kim,
C. D. Arvis,
K. KΓΆlbeck,
S. Laurie,
C. Tsai,
M. Shahidi,
Miyoung Kim,
D. Massey,
V. Zazulina,
L. Paz-Ares
|
9 |
2016 |
9
π
|
|
π
|
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
13 auth.
J. Yang,
L. Sequist,
Sarayut Lucien Geater,
C. Tsai,
T. Mok,
M. Schuler,
N. Yamamoto,
Chong-Jen Yu,
S. Ou,
Caicun Zhou,
...
D. Massey,
V. Zazulina,
Yi-long Wu
|
9 |
2015 |
9
π
|
|
π
|
Empagliflozin in Patients with Chronic Kidney Disease
39 auth.
W. Herrington,
N. Staplin,
C. Wanner,
J. B. Green,
S. Hauske,
J. Emberson,
D. Preiss,
P. Judge,
Kaitlin J. Mayne,
S. Ng,
E. Sammons,
D. Zhu,
M. Hill,
W. Stevens,
K. Wallendszus,
...
S. Brenner,
A. Cheung,
Zhi-Hong Liu,
Jing Li,
L. Hooi,
Wen Liu,
T. Kadowaki,
M. Nangaku,
A. Levin,
D. Cherney,
A. Maggioni,
R. Pontremoli,
R. Deo,
S. Goto,
X. RossellΓ³,
K. Tuttle,
D. Steubl,
M. Petrini,
D. Massey,
Jens Eilbracht,
M. Brueckmann,
M. Landray,
C. Baigent,
R. Haynes
|
9 |
2022 |
9
π
|
|
π
|
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial
8 auth.
P. Barone,
W. Poewe,
S. Albrecht,
C. Debieuvre,
D. Massey,
O. Rascol,
...
E. Tolosa,
D. Weintraub
|
8 |
2010 |
8
π
|
|
π
|
FirstβLine Afatinib versus Chemotherapy in Patients with NonβSmall Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
11 auth.
M. Schuler,
Yi-long Wu,
V. Hirsh,
K. O'Byrne,
N. Yamamoto,
T. Mok,
...
S. Popat,
L. Sequist,
D. Massey,
V. Zazulina,
J. Yang
|
8 |
2016 |
8
π
|
|
π
|
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
12 auth.
J. Yang,
V. Hirsh,
M. Schuler,
N. Yamamoto,
K. O'Byrne,
T. Mok,
...
V. Zazulina,
M. Shahidi,
J. Lungershausen,
D. Massey,
M. Palmer,
L. Sequist
|
8 |
2013 |
8
π
|
|
π
|
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
19 auth.
M. Schuler,
N. Yamamoto,
K. O'Byrne,
V. Hirsh,
T. Mok,
Sarayut Lucien Geater,
S. Orlov,
C. Tsai,
M. Boyer,
W. Su,
...
J. Bennouna,
T. Kato,
V. Gorbunova,
K. Lee,
R. Shah,
D. Massey,
R. Lorence,
M. Shahidi,
L. Sequist
|
7 |
2012 |
7
π
|
|
π
|
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
21 auth.
J. Yang,
L. Sequist,
C. Zhou,
M. Schuler,
Sarayut Lucien Geater,
T. Mok,
C. Hu,
N. Yamamoto,
J. Feng,
K. O'Byrne,
...
S. Lu,
V. Hirsh,
Y. Huang,
M. Sebastian,
I. Okamoto,
N. Dickgreber,
R. Shah,
A. MaΜrten,
D. Massey,
S. Wind,
Y. Wu
|
7 |
2016 |
7
π
|
|
π
|
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial
11 auth.
A. Schapira,
M. Mcdermott,
P. Barone,
C. Comella,
S. Albrecht,
H. Hsu,
...
D. Massey,
Y. Mizuno,
W. Poewe,
O. Rascol,
K. Marek
|
7 |
2013 |
7
π
|
|
π
|
A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
8 auth.
E. Bateman,
D. Tashkin,
N. Siafakas,
R. Dahl,
L. Towse,
D. Massey,
...
D. Pavia,
N. Zhong
|
6 |
2010 |
6
π
|
